Clinical Trials Browser

Adenocarcinoma Of Esophagus, Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT03751761 2024-02-28

GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study

Phase 1/2 Completed

58 enrolled

Gastrointestinal

Stomach Neoplasms

NCT06255262 2024-02-13

Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

Phase 1/2 Unknown

30 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT03376659 2024-02-05

Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma

Phase 1/2 Terminated

8 enrolled 14 charts

Gastrointestinal

Pancreatic Neoplasms, Colorectal Neoplasms

NCT06111326 2023-11-01

BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma

Phase 1/2 Not yet recruiting

83 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT03206073 2023-10-24

A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer

Phase 1/2 Completed

34 enrolled 18 charts

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT03611556 2023-10-03

MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.

Phase 1/2 Completed

213 enrolled 42 charts

Gastrointestinal

Carcinoma, Pancreatic Neoplasms

NCT03970616 2023-07-12

DEDUCTIVE

Phase 1/2 Terminated

27 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT04696848 2023-04-21

The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors

Phase 1/2 Terminated

25 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT04124991 2023-03-16

SOLID

Phase 1/2 Completed

24 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT03202758 2023-02-10

MEDITREME

Phase 1/2 Completed

57 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT02963831 2022-12-22

A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies

Phase 1/2 Completed

67 enrolled 16 charts

GastrointestinalGynecologic

Appendiceal Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT05327582 2022-04-14

An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC

Phase 1/2 Unknown

65 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Pancreatic Neoplasms

NCT02311361 2021-04-20

Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer

Phase 1/2 Completed

65 enrolled 17 charts

Gastrointestinal

Pancreatic Neoplasms

NCT02403271 2019-01-03

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors

Phase 1/2 Completed

124 enrolled 17 charts

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pancreatic Neoplasms

Clinical Trials

MEDIOLA

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC

BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma

DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers

CAMILLA

CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers

A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

SEPION

Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer

Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma

ABIMMUNE

DURIPANC

ICC

Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer

GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study

Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma

BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma

A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer

MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.

DEDUCTIVE

The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors

SOLID

MEDITREME

A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies

An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC

Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors